rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2012-8-6-826-830rpcardio-644Research ArticleCURRENT QUESTIONS OF CLINICAL PHARMACOLOGYАКТУАЛЬНЫЕ ВОПРОСЫ КЛИНИЧЕСКОЙ ФАРМАКОЛОГИИSARTANS AND ANGIOTENSIN CONVERTING ENZYME INHIBITORS: A DUEL BETWEEN TWO LEADERS OF PHARMACOTHERAPY OF CARDIOVASCULAR DISEASESСАРТАНЫ И ИНГИБИТОРЫ АНГИОТЕНЗИНПРЕВРАЩАЮЩЕГО ФЕРМЕНТА: ПОЕДИНОК ДВУХ ЛИДЕРОВ ФАРМАКОТЕРАПИИ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙГямджянК. А.GyamdzhyanK. A.

аспирант кафедры клинической фармакологии и пропедевтики внутренних болезней

МаксимовМ. Л.MaksimovM. L.

д.м.н., профессор кафедры клинической фармакологии и пропедевтики внутренних болезней

maksim_maksimov@mail.ruПервый Московский государственный медицинский университет им. И.М. СеченоваРоссияI.M. Setchenov First Moscow State Medical UniversityRussian Federation20120901201686826830Copyright © Gyamdzhyan K.A., Maksimov M.L., 20152015Гямджян К.А., Максимов М.Л.Gyamdzhyan K.A., Maksimov M.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/644

Topical issues of cardiovascular disease pharmacotherapy influencing function of the renin-angiotensin-aldosterone system are discussed. Efficacy and safety of two major cardiovascular drug classes, angiotensin converting enzyme inhibitors and sartans, are compared. Data from evidence base of the both drug classes are presented.

Рассматривают актуальные вопросы фармакотерапии сердечно-сосудистых заболеваний, в основе которой лежит влияние на функцию ренин-ангиотензин-альдостероновой системы. Сопоставляют эффективность и безопасность двух основных классов кардиологических препаратов — сартанов и ингибиторов ангиотензин-превращающего фермента, приводят данные доказательной базы обоих классов препаратов.

ренин-ангиотензин-альдостероновая системасартаныингибиторы ангиотензин-превращающего ферментафармакотерапия сердечно-сосудистых заболеванийкаптоприлэналаприлрамиприллозартанвалсартанирбесартанэндотелиальная функцияатеросклерозrenin-angiotensin-aldosterone systemsartansangiotensin converting enzyme inhibitorspharmacotherapy of cardiovascular diseasescaptoprilenalaprilramiprillosartanvalsartanirbesartanendothelial functionatherosclerosisReferencesDavis J.O. The second Volhard Lecture: the use of blocking agents to define the functions of the reninangiotensin system. Clin Sc Mol Med Suppl 1975; 2:3s–14s.Davis J.O. The second Volhard Lecture: the use of blocking agents to define the functions of the reninangiotensin system. Clin Sc Mol Med Suppl 1975; 2:3s–14s.Gavras H., Brunner H.R., Turini G.A. et al. Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N Engl J Med 1978; 298(18):991–5.Gavras H., Brunner H.R., Turini G.A. et al. Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N Engl J Med 1978; 298(18):991–5.Dzau V.J. Antman E.M., Black H.R. et al. The cardiovascular disease continuum validated: clinical evidence of improved patients outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 2006; 114(25):2850–70.Dzau V.J. Antman E.M., Black H.R. et al. The cardiovascular disease continuum validated: clinical evidence of improved patients outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 2006; 114(25):2850–70.Ageev F.T., Arutyunov G.P., Belenkov Yu.N. Chronic heart failure. Moscow: GEOTAR-Media; 2010. Russian (Агеев Ф.Т., Арутюнов Г.П., Беленков Ю.Н. Хроническая сердечная недостаточность. М: ГЕО-ТАР-Медиа; 2010).Ageev F.T., Arutyunov G.P., Belenkov Yu.N. Chronic heart failure. Moscow: GEOTAR-Media; 2010. Russian (Агеев Ф.Т., Арутюнов Г.П., Беленков Ю.Н. Хроническая сердечная недостаточность. М: ГЕО-ТАР-Медиа; 2010).Skvortsov A.A., Mareev V.Yu., Belenkov Yu.N. Place of angiotensin II receptor blockers in the treatment of patients with CHF. Serdtse 2008; (5): 275–83. Russian (Скворцов А.А., Мареев В.Ю., Беленков Ю.Н. Место блокаторов рецепторов ангиотензина II в лечении больных ХСН. Сердце 2008; (5): 275–83).Skvortsov A.A., Mareev V.Yu., Belenkov Yu.N. Place of angiotensin II receptor blockers in the treatment of patients with CHF. Serdtse 2008; (5): 275–83. Russian (Скворцов А.А., Мареев В.Ю., Беленков Ю.Н. Место блокаторов рецепторов ангиотензина II в лечении больных ХСН. Сердце 2008; (5): 275–83).Belenkov Yu.N. Mareev V.Yu. Ageev F.T. Chronic heart failure. Selected lectures on cardiology. Moscow: GEOTAR-Media; 2006. Russian (Беленков Ю.Н. Мареев В.Ю. Агеев Ф.Т. Хроническая сердечная недостаточность. Избранные лекции по кардиологии. М: ГЕОТАР-Медиа; 2006).Belenkov Yu.N. Mareev V.Yu. Ageev F.T. Chronic heart failure. Selected lectures on cardiology. Moscow: GEOTAR-Media; 2006. Russian (Беленков Ю.Н. Мареев В.Ю. Агеев Ф.Т. Хроническая сердечная недостаточность. Избранные лекции по кардиологии. М: ГЕОТАР-Медиа; 2006).Ostroumova O.D., Maksimov M.L., Shchukina G.N., Shorikova E.G. Receptor antagonists angiotenzinuIIv 2010: what's new? Sistemnye Gipertenzii 2011; (1): 12–15. Russian (Остроумова О.Д., Максимов М.Л., Щукина Г.Н., Шорикова Е.Г. Антагонисты рецепторов к ангиотензинуIIв 2010: что нового? Системные Гипертензии 2011; (1): 12–15).Ostroumova O.D., Maksimov M.L., Shchukina G.N., Shorikova E.G. Receptor antagonists angiotenzinuIIv 2010: what's new? Sistemnye Gipertenzii 2011; (1): 12–15. Russian (Остроумова О.Д., Максимов М.Л., Щукина Г.Н., Шорикова Е.Г. Антагонисты рецепторов к ангиотензинуIIв 2010: что нового? Системные Гипертензии 2011; (1): 12–15).Maksimov M.L., Dralova O.V., Starodubtsev A.K. AT1-receptor antagonists, angiotensin II, an-giotensin-converting enzyme in the regulation of hemodynamics and the renin-angiotensin-aldosterone system. Focus on organoprotective effects. Kardiovaskulyarnaya Terapiya i Profilaktika 2010; 9(2): 115– 124. Russian (Максимов М.Л., Дралова О.В., Стародубцев А.К. Антагонисты АТ1-рецепторов ангиотензина II, ингибиторы ангиотензин-превращающего фермента в регуляции гемодинамики и активности ренин-ангиотензин-альдостероновой системы. Фокус на органопротективные эффекты. Кардиоваскулярная Терапия и Профилактика 2010; 9(2): 115–124).Maksimov M.L., Dralova O.V., Starodubtsev A.K. AT1-receptor antagonists, angiotensin II, an-giotensin-converting enzyme in the regulation of hemodynamics and the renin-angiotensin-aldosterone system. Focus on organoprotective effects. Kardiovaskulyarnaya Terapiya i Profilaktika 2010; 9(2): 115– 124. Russian (Максимов М.Л., Дралова О.В., Стародубцев А.К. Антагонисты АТ1-рецепторов ангиотензина II, ингибиторы ангиотензин-превращающего фермента в регуляции гемодинамики и активности ренин-ангиотензин-альдостероновой системы. Фокус на органопротективные эффекты. Кардиоваскулярная Терапия и Профилактика 2010; 9(2): 115–124).Kobalava Zh.D., Kotovskaya Yu.V., Moiseev V.S. Hypertension. The keys to the diagnosis. Moscow: GEOTAR-Media; 2009. Russian (Кобалава Ж.Д., Котовская Ю.В., Моисеев В.С. Артериальная гипертензия. Ключи к диагностике. M: ГЕОТАР-Медиа; 2009).Kobalava Zh.D., Kotovskaya Yu.V., Moiseev V.S. Hypertension. The keys to the diagnosis. Moscow: GEOTAR-Media; 2009. Russian (Кобалава Ж.Д., Котовская Ю.В., Моисеев В.С. Артериальная гипертензия. Ключи к диагностике. M: ГЕОТАР-Медиа; 2009).Kobalava Zh.D., Shavarova E.K. AngiotenzinuII receptor antagonists in cardiology practice: a modern approach to the problem. Russkiy Meditsinskiy Zhurnal 2008; (11): 1609–15. Russian (Кобалава Ж.Д., Шаварова Е.К. Антагонисты рецепторов к ангиотензинуII в кардиологической практике: современный взгляд на проблему. Русский Медицинский Журнал 2008; (11): 1609–15).Kobalava Zh.D., Shavarova E.K. AngiotenzinuII receptor antagonists in cardiology practice: a modern approach to the problem. Russkiy Meditsinskiy Zhurnal 2008; (11): 1609–15. Russian (Кобалава Ж.Д., Шаварова Е.К. Антагонисты рецепторов к ангиотензинуII в кардиологической практике: современный взгляд на проблему. Русский Медицинский Журнал 2008; (11): 1609–15).The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the North Scandinavian Survival Study (CONSENSUS). N Engl J Med 1987; 316:1429–35.The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the North Scandinavian Survival Study (CONSENSUS). N Engl J Med 1987; 316:1429–35.Lindholm L.H., Ibsen H., Dahlof B. et al.; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint Reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359(9311):1004–10.Lindholm L.H., Ibsen H., Dahlof B. et al.; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint Reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359(9311):1004–10.Mochizuki S, Dahlof B, Taniguchi I et al. for the JIKEI HEART Study Group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomized, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369: 1431–9.Mochizuki S, Dahlof B, Taniguchi I et al. for the JIKEI HEART Study Group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomized, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369: 1431–9.Parving HH, Lenhert H, Bröchner-Mortensen J, et al. The effects of irbesartan on the development of diabetic nephropathy in patients with types 2 diabetes. N Engl J Med 2001;345(12):870–8Parving HH, Lenhert H, Bröchner-Mortensen J, et al. The effects of irbesartan on the development of diabetic nephropathy in patients with types 2 diabetes. N Engl J Med 2001;345(12):870–8Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–60.Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–60.Viberti G., Wheeldom N.M. MicroAlbuminuria Reduction With Valsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type II diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106(6):672–8.Viberti G., Wheeldom N.M. MicroAlbuminuria Reduction With Valsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type II diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106(6):672–8.Brenner B.M., Cooper M.E., de Zeeuw D. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2001;345(12):851–60.Brenner B.M., Cooper M.E., de Zeeuw D. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2001;345(12):851–60.Schrader J, Lüders S, Kulschewski A et al. Morbidity and Mortality after Stroke, Eprosartan compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005;36(2):1218–1226.Schrader J, Lüders S, Kulschewski A et al. Morbidity and Mortality after Stroke, Eprosartan compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005;36(2):1218–1226.Julius S., Kjeldsen S.E., Weber M. et al Outcome in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomized trial. Lancet 2004;363(9426):2022–31.Julius S., Kjeldsen S.E., Weber M. et al Outcome in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomized trial. Lancet 2004;363(9426):2022–31.The NAVIGATOR Study Group. Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. N Engl J Med 2010; 362:1477–90.The NAVIGATOR Study Group. Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. N Engl J Med 2010; 362:1477–90.Hollenberg NK, Parving HH, Viberti G, Remuzzi G. The Diovan reduction of Proteinuria Drop study: Albuminuria response to high doses of Valsartan in Type 2 Diabetes Mellitus. Circulation 2006; 114:II– 61Hollenberg NK, Parving HH, Viberti G, Remuzzi G. The Diovan reduction of Proteinuria Drop study: Albuminuria response to high doses of Valsartan in Type 2 Diabetes Mellitus. Circulation 2006; 114:II– 61National guidelines for the diagnosis and treatment of hypertension (fourth revision). Sistemnye Gipertenzii 2010; (3): 5–26. Russian (Национальные рекомендации по диагностике и лечению артериальной гипертонии (четвертый пересмотр). Системные гипертензии 2010; (3): 5–26).National guidelines for the diagnosis and treatment of hypertension (fourth revision). Sistemnye Gipertenzii 2010; (3): 5–26. Russian (Национальные рекомендации по диагностике и лечению артериальной гипертонии (четвертый пересмотр). Системные гипертензии 2010; (3): 5–26).Pitt B., Poole-Wilson P.A., Segal R. et al. Effect of losartan compared to captopril on mortality in patients with symptomatic heart failure; randomized trial — the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355(9215):1582–7Pitt B., Poole-Wilson P.A., Segal R. et al. Effect of losartan compared to captopril on mortality in patients with symptomatic heart failure; randomized trial — the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355(9215):1582–7Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Lancet 2002;360(9335):752–60Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Lancet 2002;360(9335):752–60Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893–906Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893–906Cohn J.N., Tognoni G. Valsartan Heart Failure Trial Investigator. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345(23):1667–75Cohn J.N., Tognoni G. Valsartan Heart Failure Trial Investigator. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345(23):1667–75Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772–776.Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772–776.Baker W.L., Coleman C.I., Kluger J., et al. Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II–Receptor Blockers for Ischemic Heart Disease. Ann Intern Med 2009;151:861–871Baker W.L., Coleman C.I., Kluger J., et al. Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II–Receptor Blockers for Ischemic Heart Disease. Ann Intern Med 2009;151:861–871Matchar DB, McCory DC, Orlando LA, et al Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers for Treating Essential Hypertension. Ann Intern Med 2008;148:16–29.Matchar DB, McCory DC, Orlando LA, et al Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers for Treating Essential Hypertension. Ann Intern Med 2008;148:16–29.Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin-Angiotensin System on Proteinuria in Renal Disease. Ann Intern Med 2008;148:30–48.Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin-Angiotensin System on Proteinuria in Renal Disease. Ann Intern Med 2008;148:30–48.Yusuf S., Teo K.K., Pogue J et al.; ONTARGET Investigators. Telmisartan, Ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358(15):1547–59Yusuf S., Teo K.K., Pogue J et al.; ONTARGET Investigators. Telmisartan, Ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358(15):1547–59Wang L, Huang XS, Zhou YL et al. Effects of angiotensin blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function in type 2 diabetic patients with atherosclerosis: a comparative study. Di Yi Jun Yi Da Xue Xue Bao 2005;25(8):967–71.Wang L, Huang XS, Zhou YL et al. Effects of angiotensin blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function in type 2 diabetic patients with atherosclerosis: a comparative study. Di Yi Jun Yi Da Xue Xue Bao 2005;25(8):967–71.

The authors declare that there are no conflicts of interest present.